Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CALCRLCHRM1CHRM2CHRM3F2RMAOAMAOBMAP2K1MAP2K2NTRK1NTRK2NTRK3OPRD1OPRK1OPRM1P2RY12PKLRSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC18A2SLC6A2SLC6A3TLR7TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8dacAdacBdacCfolAftsImrcAmrcBmrdApolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmB1rpmB2rpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsR1rpsR2rpsSrpsTrpsUrpsZykgMykgO
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL2379847 | 0.89 | ALOX15 (0.41) | ALOX15KDM4EBLMCYP2D6CYP2C19 | |
| SCHEMBL643463 | 0.87 | — | — | |
| Bromide SCHEMBL23123928 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL2377983 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL16323029 | 0.81 | — | — | |
| Sulfuric Acid SCHEMBL31317649 | 0.81 | KDM4E (0.41) | ALOX15KDM4EBLMCYP2D6CYP2C19 | |
| Acetic Acid SCHEMBL31317504 | 0.80 | ALOX15 (0.52) | ALOX15KDM4ECYP2D6ALDH1A1LMNA | |
| Urethane SCHEMBL5455093 | 0.77 | ALOX15 (0.79) | ALOX15BLMCYP2C19ALDH1A1LMNA | |
| Urethane SCHEMBL15486414 | 0.77 | ALOX15 (0.79) | ALOX15BLMCYP2C19ALDH1A1LMNA | |
| SCHEMBL1891967 | 0.77 | ALOX15 (0.42) | ALOX15CYP2D6CYP2C19ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462497-A | Pyridopyrimidinone Process for the preparation of compounds | 上海皓元医药股份有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-20250235390-A1 | Composition and Process for Treating a Disorder in the Oral Cavity of a Mammal | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2025-07-24 | — | — | US | disclosed |
| EP-3534867-B1 | MEDICAL COMPOSITION CONTAINING GUANIDINYL-CONTAINING POLYMER(S) AND CARRAGEENANE(S) | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-3534866-B1 | METHOD OF DENTAL RETRACTION WITH COMPOSITION WITH GUANIDINYL-CONTAINING POLYMER | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12295369-B2 | Articles containing a crosslinked guanidinyl-containing polymer and uses thereof | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-05-13 | — | — | US | disclosed |
| CN-119896762-A | Process monitoring device | 舒万诺知识产权公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20250082440-A1 | Composition for Isolating Tissue | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2025-03-13 | — | — | US | disclosed |
| CN-119462497-A | Pyridopyrimidinone Process for the preparation of compounds | 上海皓元医药股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4419062-A1 | COMPOSITION AND PROCESS FOR TREATING A DISORDER IN THE ORAL CAVITY OF A MAMMAL | Solventum Intellectual Properties Company (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-114173560-B | Articles comprising crosslinked guanidine-containing polymers and uses thereof | 舒万诺知识产权公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20130217032-A1 | LIGAND FUNCTIONALIZED POLYMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-08-22 | — | — | US | disclosed |
| US-8435776-B2 | Ligand functionalized polymers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2542889-A1 | LIGAND GUANIDINYL FUNCTIONALIZED POLYMERS | 3M Innovative Properties Company (US) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011109151-A1 | LIGAND GUANIDINYL FUNCTIONALIZED POLYMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-09-09 | — | — | WO | disclosed |
| US-20110217752-A1 | LIGAND FUNCTIONALIZED POLYMERS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-09-08 | — | — | US | disclosed |
| US-5552546-A | Process for the preparation of 2-ethoxy-4,6-dihydroxypyrimidine | DOWELANCO (US) | 1996-09-03 | — | — | US | disclosed |
| US-5463055-A | Reacting O-ethylisourea (or salt) with an alcoholate and/or a malonic acid dialkyl ester derivative, then acidification, desalting | SKW TROSTBERG AKTIENGESELLSCHAFT (DE) | 1995-10-31 | — | — | US | disclosed |
| US-4709032-A | VASODILATION AND HYPOTENSIVE AGENT | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1987-11-24 | — | — | US | disclosed |
| US-4634770-A | VASODILATORS, HYPOTENSIVES | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1987-01-06 | — | — | US | disclosed |
| EP-0109023-A1 | Isoquinolinesulfonamide derivatives and process for the preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12295369-B2 | Articles containing a crosslinked guanidinyl-containing polymer and uses thereof | C5, YTHDC1, PRMT1 | ALOX15 2868/4885KDM4E 960/4885BLM 898/4885 |
| US-20250235390-A1 | Composition and Process for Treating a Disorder in the Oral Cavity of a Mammal | GSDMD, PIGS, GANC | ALOX15 277/4885KDM4E 3077/4885BLM 1716/4885 |
| US-20110217752-A1 | LIGAND FUNCTIONALIZED POLYMERS | SELPLG, CD69, SIGLEC7 | ALOX15 2901/4885KDM4E 4413/4885BLM 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.